GSK (LON:GSK) Insider Julie Brown Buys 7 Shares

GSK plc (LON:GSK) insider Julie Brown acquired 7 shares of the stock in a transaction dated Tuesday, May 12th. The stock was acquired at an average price of GBX 1,866 per share, with a total value of £130.62.

Julie Brown also recently made the following trade(s):

• On Monday, April 13th, Julie Brown acquired 5 shares of GSK stock. The shares were purchased at an average cost of GBX 2,171 per share, for a total transaction of £108.55.

GSK Stock Performance

GSK stock traded down GBX 11 on Thursday, hitting GBX 1,875. The company had a trading volume of 41,102,586 shares, compared to its average volume of 9,575,882. The stock has a market cap of £74.85 billion, a price-to-earnings ratio of 13.19, a P/E/G ratio of 1.24 and a beta of 0.30. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The stock’s 50-day simple moving average is GBX 2,037.83 and its 200 day simple moving average is GBX 1,938.72. GSK plc has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282.

GSK (LON:GSK) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. The business had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. As a group, equities research analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Tuesday, April 14th. Citigroup cut their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a report on Wednesday, May 6th. Finally, Shore Capital Group reiterated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GSK has an average rating of “Hold” and a consensus price target of GBX 2,034.29.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.